New drug for non-Hodgkin lymphoma, chronic lymphocytic leukemia passes early test

The drug,
alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be
very active during cell division. The present study, published in the journalInvestigational
New Drugs, looks at the safety, tolerability, and preliminary success of
alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic
leukemia (CLL).

"An advantage with this drug is it is oral and very effective in a significant number of patients with aggressive lymphoma when used at that dose for 7  days out a 21 day cycle," said hematologist Swaminathan Iyer, M.D., who led the multi-site study. 

Drugs commonly used to treat NHL and CLL are chemotherapeutic drugs and some biological targeted agents such as the monoclonal antibodies rituximab, ofatumumab and obinutuzumab with varying degrees of success.

Although about 1/2 of patients participating in the phase I study experienced side effects most of which were manageable events, Iyer said that is not unusual for such
biologic (non chemotherapy) drugs.

"The side effects were fairly tolerable in this study," Iyer said. "We would like to see more information from a larger group of patients to fully understand the drug's safety and tolerability for those experiencing the middle-to-later stages of these diseases."

Iyer and his group recommend 50 mg, twice-daily doses of alisertib for the advanced phase trials of the drug, which Iyer says has begun enrollment. Alisertib is not yet approved for general medical use by the FDA. Its impact on T cell lymphoma is being investigated in a separate, phase III trial for a specific type of  lymphoma called the T cell lymphomas. Houston Methodist is a participating study site for that project. Initial phase II reports in these T cell lymphomas showed a 57% response, the highest ever noted for any single agent in this disease entity.

New drug
for non-Hodgkin lymphoma, chronic lymphocytic leukemia passes early test